1. Home
  2. GILD

GILD

Gilead Sciences Inc.

Logo Gilead Sciences Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Founded: 1987 Country:
United States
United States
Employees: N/A City: FOSTER CITY
Market Cap: 86.6B IPO Year: 1992
Target Price: $85.85 AVG Volume (30 days): 7.4M
Analyst Decision: Buy Number of Analysts: 13
Dividend Yield: 4.54% Dividend Payout Frequency: Quarterly
EPS: 4.50 EPS Growth: 23.63
52 Week Low/High: $67.62 - $87.87 Next Earning Date: 04-25-2024
Revenue: $27,116,000,000 Revenue Growth: -0.60%
Revenue Growth (this year): 3.42% Revenue Growth (next year): 1.98%

Share on Social Networks: